Vestal Point Capital’s Bristol-Myers Squibb BMY Stock Holding History

Vestal Point Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.1M	Sell	800,000 -200,000	-20%	-$11.5M	1.08%	28
2026 Q1	$60.6M	Buy	1,000,000 +750,000	+300%	+$43.7M	1.7%	19
2025 Q4	$13.5M	Buy	+250,000	New	+$12M	0.46%	46
2024 Q4	–	Sell	-250,000	Closed	-$12.9M	–	80
2024 Q3	$12.9M	Sell	250,000 -250,000	-50%	-$11.7M	0.98%	28
2024 Q2	$20.8M	Buy	+500,000	New	+$22.4M	1.55%	23

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vestal Point Capital's BMY Position: Q2 2026 in Review

Vestal Point Capital reduced its Bristol-Myers Squibb (BMY) stake by 20% in Q2 2026, selling an estimated $11.5M and leaving 800,000 shares worth $46.1M. The position accounts for 1.08% of the portfolio, ranked #28.

Vestal Point Capital first reported a position in BMY in Q2 2024 and has held it in 5 quarters since. The position peaked at $60.6M in Q1 2026. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Vestal Point Capital held 800,000 shares of Bristol-Myers Squibb worth $46.1M as of Q2 2026.
Vestal Point Capital sold 200,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $11.5M.
Bristol-Myers Squibb made up 1.08% of Vestal Point Capital's portfolio in Q2 2026, its #28 holding.
Vestal Point Capital first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 5 quarters since.
Vestal Point Capital's Bristol-Myers Squibb position peaked at $60.6M in Q1 2026.
2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.